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Abstract
Background We sought to estimate the prevalence of polypharmacy, the most prevalent drug classes involved, and the 
prevalence and type of potentially inappropriate prescribing among older male and female patients in family medicine.
Methods We conducted a secondary analysis of baseline data from a pragmatic cluster-randomised trial on the efficacy of a 
screening and management tool for geriatric syndromes among older community-dwelling patients (aged ≥ 75 years) included 
by 42 family physicians. Information on drug prescription and clinical diagnoses (International Classification of Primary 
Care—2nd Edition [ICPC-2] coded) were extracted manually from medical records. The prevalence of polypharmacy, defined 
as the use of at least five permanent oral or parenteral drugs, and of potentially inappropriate medications (PIMs), identified 
according to 2015 updated Beers criteria, were compared between men and women.
Results We included 429 patients (269 women and 160 men; mean age 82.9 and 81.8 years, respectively). Polypharmacy 
was found in 59.9% of them. Analgesics, antithrombotic agents and agents acting on the renin-angiotensin system were the 
most frequently prescribed drug categories. Three-quarters of patients (76.7%) were prescribed at least one PIM according 
to Beers criteria, without difference by sex/gender (p = 0.760). The most frequent PIMs were proton-pump inhibitors used 
for > 8 weeks, diuretics, benzodiazepines, aspirin for primary prevention, and chronic use of non-steroidal anti-inflammatory 
drugs. Prescription patterns markedly differed by sex/gender, but the number and patterns of inappropriate prescriptions 
were comparable overall.
Interpretation Both polypharmacy and PIMs were very common in older patients followed regularly in family medicine in 
Switzerland. Interestingly, most PIMs involved only a limited number of medication classes.
Trial registration Clinicaltrials.gov NCT 02618291.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4080 1-019-00175 -6) contains 
supplementary material, which is available to authorized users.
 * Yolanda Mueller 
 Yolanda.mueller@unisante.ch
1 University of Lausanne, Lausanne, Switzerland
2 Department of Family Medicine/Center for Primary Care 
and Public Health (Unisanté), University of Lausanne, 
Lausanne, Switzerland
1 Introduction
Polypharmacy and inappropriate prescribing are impor-
tant clinical challenges, especially among older patients, 
who often have multiple chronic conditions. Polyphar-
macy is heterogeneously defined in studies as the use of 
multiple medications by the patient, although most studies 
agree on a threshold of at least five medications [1]. In 
Switzerland, one-quarter of community-dwelling patients 
aged > 65 years self-report taking five or more drugs [2], 
although higher rates have been reported based on claims 
data [3, 4].
Polypharmacy is associated with potentially inappro-
priate medications (PIMs) [5]. The prevalence of PIM 
varies according to age, context (community dwelling vs. 
care home) and the criteria used to define it [6–8]. Swiss 
data in community-dwelling patients aged > 65  years 
reported a prevalence of PIM around 20% [3, 9, 10], 
increasing to 74% in nursing home residents [4]. How-
ever, these studies were limited to claims data or con-
ducted in specific populations, and clinical information 
to estimate inappropriate prescribing was often weak. The 
most prevalent classes of PIM were psycholeptic agents, 
followed by sex hormones and genital system modulators, 
psychoanaleptics, anti-inflammatory and anti-rheumatic 
products and cardiac therapy [3]. Still, detailed data on 
prescriptions patterns, polypharmacy and PIM remain 
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limited in Switzerland, especially for patients followed-
up in family medicine.
Sex/gender differences have been reported in the prev-
alence of both polypharmacy and PIM. In the adult popu-
lation, men are prescribed fewer drugs than are women, 
even after excluding sex/gender-related morbidity, 
although the difference decreases with age [11]. Among 
older populations, evidence on gender difference in poly-
pharmacy varies, but older women seem to receive more 
PIMs [8, 12–14]. When studies do report gender differ-
ences, they most often lack further exploration or expla-
nation of the gender discrepancy. Hofer-Dückelmann [15] 
explored the reasons for higher rates of polypharmacy in 
older women, highlighting the gendered differences in 
attitudes towards drug intake: the female propensity to 
see a physician and discuss problems, family responsibil-
ity and caregiving activities, provider–patient relation-
ship, education, social deprivation and self-rated health. 
Differences in drug prescriptions have been studied in 
the field of cardiovascular prevention, with a Swedish 
study observing that older women were more likely to be 
treated with diuretics and nitro-glycerine, whereas older 
men with diabetes were more likely to receive antihyper-
glycaemic drugs [16]. Other studies have shown that older 
women receive more psychotropic medications [17–19]. 
Until now, sex/gender differences in drug prescriptions 
have not been explored in the Swiss context.
This study aims to provide insight into drug prescription 
patterns in male and female older patients followed in family 
medicine in the French-speaking part of Switzerland. The 
objectives were to estimate the prevalence of polypharmacy, 
the most prevalent drug classes, the prevalence of PIM and 
type and, last, the association between polypharmacy/PIMs 
and the sex/gender of patients.
2  Method
2.1  Study Design
We conducted a secondary analysis of baseline data from 
a pragmatic cluster-randomised trial on the efficacy of a 
screening and management tool for geriatric syndromes 
in family medicine (NCT 02618291). In this trial, 42 pri-
vate family medicine practices in western Switzerland, 
selected according to their willingness to participate in the 
trial, included at least ten community-dwelling patients 
(aged ≥ 75 years), randomly selected among routinely fol-
lowed patients (at least two visits in the past year) between 
September 2016 and January 2018.
2.2  Drug Use and Clinical Information
Information on drug prescription and clinical diagnosis 
was extracted manually from paper or electronic medical 
records by a trained research assistant and entered into a 
standardised and pretested case report form. Designation 
was matched with corresponding anatomical therapeutic 
chemical (ATC) code classification [20] using a prede-
fined list of 2628 drugs that were commercially available 
in Switzerland. Drugs were categorised in the correspond-
ing second-level ATC class. Only oral or parenteral drugs 
were considered for this analysis. We distinguished drugs 
taken continuously from occasional medication based on 
the information recorded as comments in the case report 
form. For example, mentions of “stand-by treatment”, 
conditional use (“in case of”) and limited time (“until”) 
were considered occasional treatment. Continuous use was 
considered the default prescription in the absence of com-
ments. Patients’ chronic conditions present in the medi-
cal file were coded by the same study staff according to 
a predefined list of 75 diagnoses based on International 
Classification of Primary Care—2nd Edition (ICPC-2; 
Wonca International Classification Committee) [21]. Poly-
pharmacy was defined as the prescription of at least five 
permanent oral or parenteral drugs [22].
2.3  Potentially Inappropriate Medications (PIMs)
PIMs were identified and divided into five sections accord-
ing to 2015 updated Beers criteria [6] using the ICPC-2 
diagnosis and ATC classification: medication to avoid in 
most older patients; drug–disease or drug–syndrome inter-
actions; drugs to be used with caution in older patients; 
drug–drug interactions meaningful in a geriatric setting; and, 
finally, drugs that should be avoided or the dose reduced 
with impaired renal function. The last two sections were 
added with the 2015 update, so only the first three sections 
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were used to assess the total number of PIMs to enable com-
parison with previous studies.
2.4  Sex/Gender
Patient sex/gender categorisation was based on the infor-
mation available in the medical record as recorded by the 
physician. Because we could not disentangle the effects of 
sex (understood as biological characteristics) and gender 
(socially constructed), we refer to the combined effect of 
sex/gender [23, 24].
2.5  Data Analysis
A Wilcoxon rank-sum test was used to assess whether a 
difference existed in the number of medications between 
men and women. Proportions by sex/gender were compared 
with Chi squared and Fisher’s exact tests. We used logistic 
regression to estimate the odds ratios (ORs) of the prescrip-
tion of different drug classes by sex/gender. Considering 
that patients were recruited via their physicians, we used a 
mixed logistic regression model with a random intercept by 
physician to adjust the ORs and compared the added value 
of adding the random intercept by likelihood ratio tests. p 
values < 0.05 were considered significant. Stata software 
(version 14, College Station, TX, USA) was used to analyse 
the data.
3  Results
In total, 42 general practitioners (18 women, 24 men) par-
ticipated in the trial, each enrolling a median number of 11 
patients (interquartile range [IQR] 7–12). Final data con-
sisted of 429 patients with a median age of 82 years (IQR 
78–86), 62.7% of whom were female. Table 1 lists the soci-
odemographic and clinical characteristics of the included 
patients. Women were slightly older (82.9 vs. 81.8 years; 
p = 0.021) and were more frequently living on their own 
(64.8 vs. 26.4%; p < 0.001), receiving home-based care 
(21.3 vs. 11.3%; p = 0.009), had a lower education level 
(p < 0.001) and were less likely to drive (35.9 vs. 76.9%; 
p < 0.001). The number of ICPC-2 diagnoses was compa-
rable between men and women (p = 0.194). The proportion 
of men, compared with women, with at least one condition 
reported by ICPC-2 chapter was comparable for most chap-
ters, with the exception of eye conditions (14.1 vs. 25.6%; 
p = 0.003), musculoskeletal conditions (66.9 vs. 42.5%; 
p < 0.001) and conditions of the genital system (14.1 vs. 
34.4%; p < 0.001).
3.1  Polypharmacy and Drug Classes by Sex/Gender
Patients were prescribed a median of seven drugs (IQR 
5–10), or five drugs (IQR 3–8) when occasional medication 
was excluded, with no differences between men and women 
(p = 0.469 and p = 0.636, respectively; data not shown). The 
prevalence of polypharmacy (defined as at least five perma-
nent drugs) was 59.9% (61.9% in men; 58.7% in women; 
p = 0.521). Table 2 lists the most frequent drug classes used. 
Analgesics and antithrombotic agents were prescribed to more 
than one-half of patients. Agents acting on the renin-angioten-
sin system (48.7%), mineral supplements (44.3%) and lipid-
modifying agents (39.9%) were the next most frequent drug 
classes, followed by psycholeptics (26.6%) and drugs for acid-
related disorders (26.3%). Women were more likely to be pre-
scribed mineral supplements (54.3 vs. 27.5%; OR 3.12 [95% 
confidence interval {CI} 2.05–4.77]), psychoanaleptics (28.3 
vs. 16.9%; OR 1.94 [95% CI 1.19–3.17]) and thyroid therapy 
(16.0 vs. 5.6%; OR 3.37 [95% CI 1.60–7.10]), whereas men 
received more prescriptions for antithrombotic drugs (62.5 vs. 
43.1%; OR 0.45 [95% CI 0.30–0.68]), lipid-modifying agents 
(49.4 vs. 34.2%; OR 0.53 [95% CI 0.36–0.79]), urologicals 
(24.4 vs. 5.6%; OR 0.18 [95% CI 0.10–0.35]) and drugs used 
in diabetes (19.4 vs. 10.0%; OR 0.46 [95% CI 0.27–0.81]). 
Four drug classes were frequently prescribed for intermittent 
use: analgesics, psycholeptics, anti-inflammatory and anti-
rheumatic products and drugs for constipation. A significant 
variation of the prescription by physician, estimated by adding 
a random intercept in the model, was found for agents acting 
on the renin-angiotensin system (p = 0.007), lipid-modifying 
agents (p < 0.001), β-blocking agents (p = 0.027) and vitamins 
(p < 0.001).
3.2  PIM and Sex/Gender
The percentage of patients with at least one PIM was 
76.7%, with a median number of two PIMs per patient 
(IQR 1–3). Table 3 lists the ten most prevalent PIMs, 
representing 93.8% of all identified PIMs, along with 
the rationale for the recommendation. The most fre-
quent medications to avoid for most older adults were 
proton-pump inhibitors (PPIs) prescribed for a dura-
tion > 8  weeks (23.1% of patients), benzodiazepines 
(21.5%), chronic use of oral non-cyclooxygenase-selec-
tive non-steroidal anti-inflammatory drugs (NSAIDs) 
(16.8%) and nonbenzodiazepine/benzodiazepine receptor 
agonist hypnotics (9.8%). The most frequent drugs that 
should be used with caution in most older adults included 
diuretics (28.4% of patients), aspirin for primary preven-
tion of cardiac events (19.8%), vasodilators (15.8%) and 
selective serotonin reuptake inhibitors (SSRIs) (12.4%).
Details of all PIMs and comparison by sex/gender 
can be found in Table 1 in the Electronic Supplementary 
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Material. Combined, the number of PIMs and proportions 
of patients with at least one PIM or with different PIM 
categories were comparable between men and women (at 
least one PIM: 76.2 vs. 77.5%; p = 0.760). Sex/gender dif-
ferences were observed in terms of medication categories. 
The more frequent PIMs in women were antidepressants 
that should be avoided (4.5 vs. 0%; p = 0.010), SSRIs to be 
used with caution (15.6 vs. 6.9%; p = 0.008) and various 
psychotropic drugs to be avoided in patients with a history 
of fracture (4.5 vs. 0.6%; p = 0.025). PIMs more frequent 
in men were vasodilators to be used with caution (20.0 vs. 
11.2%; p = 0.012).
4  Discussion
Polypharmacy was very common in older patients followed 
regularly in family medicine in Switzerland, with three of 
five patients taking at least five drugs. Three-quarters of 
patients were prescribed at least one PIM according to Beers 
criteria. The most frequent PIMs were PPIs prescribed for 
a duration > 8 weeks, diuretics, benzodiazepines, aspirin 
for primary prevention of cardiac events and chronic use of 
NSAIDs. Prescription patterns markedly differed by sex/gen-
der, with more PIMs found in women, who were prescribed 
more psychotropic drugs that should be avoided or used 
with caution with regards to their age and medical condi-
tion (fracture). Variations in prescription by physician were 
observed for cardiovascular drugs and vitamins.
Table 1  Sociodemographic and clinical characteristics
Data are presented as mean ± standard deviation or N (%) unless otherwise indicated
*ICPC International Classification of Primary Care—2nd Edition; Wonca International Classification Committee
Characteristic Women (N = 269) Men (N = 160) P value
Age (years) 82.9 ± 5.2 81.8 ± 4.5 0.021
Living alone 169 (64.5) (N = 262) 42 (26.3) (N = 160) < 0.001
Driving a car 95 (35.9) (N = 265) 123 (76.9) (N = 160) < 0.001
Receiving home-based care 57 (21.2) (N = 269) 18 (11.3) (N = 160) 0.009
Receiving help from other caregivers 64 (25.3) (N = 253) 24 (16.0) (N = 150) 0.029
N = 249 N = 149
Education (degree reached) < 0.001
 Did not finish primary school 7 (2.8) 0 (0.0)
 Primary school 85 (34.1) 28 (18.8)
 Secondary school 42 (16.9) 11 (7.4)
 Professional degree 86 (34.5) 57 (38.3)
 Higher education (university or equivalent) 29 (11.7) 53 (35.6)
N = 269 N = 160
Median (interquartile range) number of chronic conditions 4 (2–5) 4 (3–6) 0.194
Chronic conditions by ICPC-2*chapter
General 17 (6.3) 8 (5.0) 0.573
Blood 34 (12.6) 22 (13.8) 0.741
Digestive system 77 (28.6) 47 (29.4) 0.868
Eye 38 (14.1) 41 (25.6) 0.003
Ear 34 (12.6) 23 (14.4) 0.609
Cardiovascular 232 (86.3) 145 (90.6) 0.179
Musculoskeletal 180 (66.9) 68 (42.5) < 0.001
Neurological 74 (27.5) 36 (22.5) 0.251
Psychological 87 (32.3) 53 (33.1) 0.867
Respiratory 38 (14.1) 33 (20.6) 0.080
Skin 44 (16.4) 26 (16.3) 0.977
Endocrine/metabolic and nutritional 125 (46.5) 66 (41.3) 0.293
Urological 75 (27.9) 43 (26.9) 0.821
Genital 38 (14.1) 55 (34.4) < 0.001
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Table 2  Oral and parenteral drug classes prescribed to patients aged ≥ 75 years followed in primary care and included in the study, by sex/gender
Drugs classed according to ATC code, second-level class. Odds ratios of class prescription by sex/gender from a logistic regression model, raw 
and after adding a random intercept by physician. Restricted to drug classes prescribed to ≥ 10% of either male or female patients
Bold formatting indicates statistical significance
AdjOr adjusted OR, ATC anatomical therapeutic chemical, CCBs calcium channel blockers, CI confidence interval, NA not applicable: non-
convergence of mixed logistic regression model, OR odds ratio, RAS renin-angiotensin system
a Baseline: Men
Drug 
class 
(ATC)
Class name All drugs 
(intermittent 
use included)
Continuous use only
Total users 
(N = 429)
Total users 
(N = 429)
Women 
(N = 269)
Men (N = 160) ORa (95% CI) AdjOR (95% 
CI)
p value for 
cluster effect
N02 Analgesics 236 (55.0) 82 (19.1) 54 (20.1) 26 (16.3) 1.29 (0.77–2.17) 1.36 (0.79–
2.35)
0.017
B01 Antithrombotic 
agents
224 (52.2) 217 (50.6) 116 (43.1) 100 (62.5) 0.45 (0.30–0.68) 0.45 (0.30–
0.68)
0.436
C09 Agents acting on 
the RAS
212 (49.4) 209 (48.7) 125 (46.5) 80 (50.0) 0.87 (0.59–1.28) 0.84 (0.56–
1.28)
0.007
A12 Mineral supple-
ments
194 (45.2) 190 (44.3) 146 (54.3) 44 (27.5) 3.13 (2.05–4.77) 3.27 (2.10–
5.08)
0.074
C10 Lipid-modifying 
agents
173 (40.3) 171 (39.9) 92 (34.2) 79 (49.4) 0.53 (0.36–0.79) 0.49 (0.32–
0.76)
< 0.001
N05 Psycholeptics 167 (38.9) 114 (26.6) 75 (27.9) 38 (23.8) 1.24 (0.79–1.95) 1.23 (0.78–
1.95)
0.372
A02 Drugs for 
acid-related 
disorders
145 (33.8) 113 (26.3) 43 (26.9) 69 (25.7) 0.94 (0.60–1.46) 0.95 (0.60–
1.51)
0.126
C07 β-blocking agents 134 (31.2) 133 (31.0) 80 (29.7) 53 (33.1) 0.85 (0.56–1.30) 0.81 (0.52–
1.26)
0.027
M01 Anti-inflam-
matory and 
antirheumatic 
products
113 (26.3) 60 (14.0) 38 (14.1) 22 (13.8) 1.03 (0.59–1.82) 1.05 (0.59–
1.88)
0.196
N06 Psychoanaleptics 109 (25.4) 103 (24.0) 76 (28.3) 27 (16.9) 1.94 (1.19–3.17) 1.94 (1.18–
3.17)
0.459
C03 Diuretics 101 (23.5) 98 (22.8) 60 (22.3) 38 (23.8) 0.92 (0.58–1.47) 0.94 (0.58–
1.51)
0.095
A06 Drugs for consti-
pation
104 (24.2) 57 (13.3) 35 (13.0) 22 (13.8) 0.94 (0.53–1.66) 0.94 (0.52–
1.70)
0.113
A11 Vitamins 72 (16.8) 71 (16.6) 47 (17.5) 24 (15.0) 1.20 (0.70–2.05) 1.33 (0.73–
2.40)
< 0.001
C08 CCBs 71 (16.6) 65 (15.2) 45 (16.7) 20 (12.5) 1.41 (0.80–2.48) NA
G04 Urologicals 58 (13.5) 53 (12.4) 15 (5.6) 39 (24.4) 0.18 (0.10–0.35) NA
A10 Drugs used in 
diabetes
58 (13.5) 58 (13.5) 27 (10.0) 31 (19.4) 0.46 (0.27–0.81) NA
H03 Thyroid therapy 53 (12.4) 52 (12.1) 43 (16.0) 9 (5.6) 3.37 (1.60–7.10) 3.51 (1.63–
7.57)
0.115
C01 Cardiac therapy 51 (11.9) 34 (7.9) 20 (7.4) 14 (8.8) 0.84 (0.41–1.71) 0.79 (0.37–
1.66)
0.093
B03 Anti-anaemic 
preparations
41 (9.6) 40 (9.3) 16 (10.0) 25 (9.3) 0.92 (0.48–1.78) 1.06 (0.50–
2.23)
< 0.001
C05 Vasoprotectives 36 (8.4) 36 (8.4) 26 (9.7) 7 (4.4) 2.34 (0.99–5.52) 2.52 (1.03–
6.16)
0.157
M04 Antigout prepara-
tions
34 (7.9) 31 (7.2) 13 (4.8) 17 (10.6) 0.43 (0.20–0.90) 0.42 (0.19–
0.90)
0.213
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4.1  Polypharmacy and Prevalence of PIM
The prevalence of both polypharmacy and PIM was com-
parable to findings in recent data from Switzerland [4] but 
higher than previous estimates [3, 9, 10]. Participants in 
our study were older than in previous studies (> 75 years in 
our study vs. > 65 years). Polypharmacy tends to increase 
with age, and many Beers criteria start to apply systemati-
cally at the age of 75 years (e.g. chronic use of NSAIDs, 
dabigatran or prasugrel) or 80 years (aspirin for primary pre-
vention). Our study highlights the high prevalence of ben-
zodiazepines, non-benzodiazepine/benzodiazepine recep-
tor agonist hypnotics, specific cardiovascular drugs, oral 
non-cyclooxygenase-selective NSAIDs for chronic use and 
SSRIs. Important differences exist between previous stud-
ies conducted in Swiss patients and our study. For example, 
aspirin for primary prevention of cardiac events by patients 
aged > 80 years and vasodilators were not reported in other 
claim-based studies, which do not have access to clinical 
information. By contrast, all these items were very common 
in our patient population, which may explain some of the 
differences in PIM prevalence [3, 10].
Among patients aged ≥ 75 years followed in family med-
icine, important differences in prescription patterns were 
observed by sex/gender. Men received more cardiovascular 
prevention drugs, whereas women received more mineral 
supplements and antidepressants, despite a similar preva-
lence of cardiovascular or psychological conditions in men 
and women. Cardiovascular drugs were also less prescribed 
in women. While some of these differences may still reflect 
true diagnosis prevalence differences, further attention 
should be given to potential under- or overdiagnosis of spe-
cific conditions in older patients, based on well-documented 
medical gender bias [15, 25].
In contrast with previous studies in which older women 
were prescribed more PIMs [8, 12, 13], we did not identify 
Table 3  The ten most prevalent PIMs according to the 2015 updated Beers criteria, and summary of the rationale for the recommendation
AF atrial fibrillation, ATC anatomical therapeutic chemical, PIM potentially inappropriate medication, NSAIDs non-steroidal anti-inflammatory 
drugs, SIADH syndrome of inappropriate antidiuretic hormone secretion, SSRI selective serotonin reuptake inhibitor
Beers criteria item ATC class N (%) Rationale
Diuretics C03 122 (28.4) Use with caution; may exacerbate or cause 
SIADH or hyponatraemia
Proton-pump inhibitors A02BC 99 (23.1) Avoid scheduled use for > 8 weeks unless in 
high-risk patients
Benzodiazepines N05BA12, N05CD04, N05BA06, 
N05BA56, N05BA04, N05CD07, 
N05CD05, N05BA05, N05BA02, 
N03AE01, N05BA01, N05BA17, 
N05CD01, N05CD10
92 (21.5) Avoid; older adults have increased sensitiv-
ity to benzodiazepines and decreased 
metabolism of long-acting agents. In 
general, all benzodiazepines increase the 
risk of cognitive impairment, delirium, 
falls, fractures and motor vehicle crashes 
in older adults
Aspirin for primary prevention of cardiac 
events
B01AC 85 (19.8) Use with caution in patients aged ≥ 80 years
Non-cyclooxygenase-selective NSAIDs, 
oral
M01A 71 (16.6) Avoid chronic use, unless other alterna-
tives are not effective and patient can take 
gastroprotective agent
Vasodilators C01D, C04, C07F 68 (15.8) Use with caution, may cause syncope
SSRIs N06AB 53 (12.4) Use with caution, may cause SIADH
Nonbenzodiazepine, benzodiazepine 
receptor agonist hypnotics
N05CF04, N05CF01, N05CF02, 
N05CF03
42 (9.8) Avoid; adverse events in older adults such 
as delirium, falls, fractures, increased 
hospitalisations
Cardiovascular (amiodarone, digoxin, 
nifedipine with immediate-release, 
doxazosin)
C02CA04, C01AA05, C01AA02, 
C01AA52, C01AA08, C08CA05, 
C08GA01, C08CA55, C07FB03, 
C02CA01, C02LE01, G04CA03, 
C02AC01, N02CX02, S01EA04, 
C02LC01, C02LC51, C02AC0, C02AB, 
C02LB, C02AA0, C02LA01, C02LA51, 
C02LA71, C02AA52, C01BA03, 
C01BD07, C01BD01
21 (4.9) Amiodarone: avoid as first-line therapy for 
AF unless patient has heart failure or left 
ventricular hypertrophy. Digoxin: avoid 
as first-line therapy for AF. Nifedipine: 
avoid, potential for hypotension and risk 
of precipitating myocardial ischaemia. 
Doxazosin: avoid as antihypertensive, risk 
of orthostatic hypotension
Association of chronic kidney disease and 
NSAIDs
M01A 21 (4.9) Avoid; may increase risk of acute kidney 
injury and further decline of renal func-
tion
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major differences in overall PIM prevalence. However, the 
sex/gender differences we found in the type of PIMs echo 
the differences found in prescription patterns: women were 
more likely to have PIMs related to antidepressants, and men 
were more likely to have PIMs related to vasodilators. Larger 
studies exploring the reasons for increased or different PIMs 
in women hypothesise on multiple biological and social fac-
tors. Sex differences in the prevalence of conditions may 
explain discrepancies in drug prescriptions (and therefore 
the risk of PIM) and may imply a different navigation of the 
health system and the number of health providers involved 
(increasing the risk of PIMs). Social factors include gender 
bias in diagnosis and treatment for similar conditions and 
the intersection of gender with other social factors, such as 
education, living conditions, communication modes and 
healthcare provider–patient interactions [14, 19].
4.2  Limitations of the Study
Our analysis of potential inappropriateness was based solely 
on the Beers criteria. We included patients who consulted 
at least twice during the last year, which may have biased 
the sample towards patients who consult often and use more 
medication. Also, physicians participating in the cluster-ran-
domised trial may not be fully representative of all Swiss 
physicians, although we tried to limit inclusion criteria as 
much as possible to align with the pragmatic nature of the 
trial. Some medical conditions (e.g. tobacco use, obesity) 
were only counted if listed in the medical file as a diagno-
sis, so may be underestimated. Creatinine clearance was not 
noted for patients with chronic kidney disease, which may 
have led to some NSAID use being misclassified as poten-
tially inappropriate. Also, the distinction between primary 
and secondary prevention relied on the cardiovascular diag-
noses mentioned in the medical file, which may also have 
been underreported. Overall, whereas we acknowledge the 
potential for misclassification for PIMs that require specific 
conditions, we believe the quality of the clinical information 
provided for these patients as part of an intervention trial to 
be better than that of routine health records or claims data. 
Finally, drug prescription is not equivalent to drug use, as 
patients may never start the prescribed drug or may stop it 
prematurely. This may have led to overestimation of polyp-
harmacy but not the estimation of potentially inappropriate 
prescriptions considering that a drug not taken is still poten-
tially inappropriately prescribed.
4.3  Clinical Implications
This study highlighted the existing challenges in the medi-
cation of older patients in Switzerland in terms of PIM 
and polypharmacy. Polypharmacy based on the number of 
medications is not necessarily inappropriate, considering 
that patients with several diagnoses and comorbidities may 
require multiple medications that may all be clinically indi-
cated. However, the risk of PIMs increases with the num-
ber of prescribed drugs. Tools to reduce PIMs, such as the 
PRISCUS list [26], Beers criteria [6], the Screening Tool of 
Older People’s Prescriptions (STOPP) and Screening Tool 
to Alert to Right Treatment (START) criteria [7], exist, but 
studies have shown that family physicians do not necessarily 
use them because of negative views [27]. Although physi-
cians are aware of PIM and polypharmacy [27], medication 
they consider as potentially inappropriate does not neces-
sarily match established criteria such as the PRISCUS list.
Interestingly, only a limited number of medication classes 
were involved in most PIMs. In this context, targeted infor-
mation on the most prevalent PIM categories, for example 
PPIs, diuretics, benzodiazepines, and aspirin for primary 
prevention (Table 3), could be more efficient than lengthy 
deprescription lists. Including some deprescription advice 
in the ‘top five’ lists as promoted by the ‘Choosing wisely’ 
campaign is probably promising, but more effort is needed 
for these recommendations to be known to and applied by 
physicians [28]. Furthermore, prescription habits for specific 
drugs such as PPIs, NSAIDs, benzodiazepines and z-drugs 
must evolve to include limited treatment durations. We high-
lighted some differences in prescription habits by sex/gen-
der, which suggested a need for physicians to reflect on their 
potential implicit gender biases in diagnosis and treatment. 
Indeed, targeted information on the most prevalent PIM 
categories, differentiating men and women, could be more 
efficient than lengthy deprescription lists. Such an approach 
should be further tested within deprescription trials.
5  Conclusions
Both polypharmacy and potentially inappropriate prescrib-
ing were very common in older patients followed in family 
medicine in Switzerland. Interestingly, only a limited num-
ber of medication classes were involved in most PIMs, and 
patterns varied by sex/gender. In this context, simple depre-
scription lists targeting the most frequently inappropriately 
prescribed drugs according to patient sex/gender could prove 
more useful than lengthy generic advice to reduce poten-
tially inappropriate prescriptions.
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